ERYTHROMYCIN
LOE ApproachingNDATOPICALSOLUTION
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
ERYTHROMYCIN by Eli Lilly and Company is clinical pharmacology erythromycin diffuses readily into most body fluids. Approved for penicillin-allergic patients, the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, the severity of the infection requires immediate high serum levels of erythromycin. First approved in 1980.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis, approved in 1980 for a broad spectrum of indications ranging from acne vulgaris and respiratory infections to off-label uses in cancer and rare genetic disorders. Available as a topical solution, it targets gram-positive and gram-negative bacteria including Streptococcus, Staphylococcus, Mycoplasma, and Chlamydia. The drug's mechanism enables activity against both common infections and emerging clinical applications in inflammatory and oncologic conditions.
LOE Approaching
As a mature, approaching-LOE product with limited commercial momentum, positions attract smaller brand teams focused on lifecycle extension and niche indication management rather than growth-stage expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin crosses the placental…
Worked on ERYTHROMYCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.